Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the ‘VEDERA’ trial

Rudresh Shukla; Paul Emery; Maya Buch

Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the ‘VEDERA’ trial

Rudresh Shukla, Paul Emery, Maya Buch

Division of Musculoskeletal & Dermatological Sciences (L5)

University of Leeds

Research output: Contribution to journal › Letter › peer-review

Original language	English
Journal	Rheumatology
Publication status	Accepted/In press - 8 Oct 2021

Embargoed Document

VEDERA_MDA_Letter_Buch_RHE-21-2108_R1_Clean
Accepted author manuscript, 45.1 KB
Embargo ends: 1/01/31

Cite this

@article{c2daca99fe8342bbab546a8dbb6de344,

title = "Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the {\textquoteleft}VEDERA{\textquoteright} trial",

author = "Rudresh Shukla and Paul Emery and Maya Buch",

year = "2021",

month = oct,

day = "8",

language = "English",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

}